HPRA

Compilation of quality review of documents (QRD) on stylistic matters in product information

Retrieved on: 
Sunday, March 10, 2024

29 February 2024

Key Points: 
    • 29 February 2024
      EMA/25090/2002 rev.23*
      Human Medicines Division

      Compilation of QRD decisions on stylistic matters in product information
      Issues
      Abbreviations

      Connected problems
      Subscript and superscript

      QRD Suggestions
      Acronyms must be written in their standard form; e.g.

    • Cmax, Cmax
      Abbreviations and

      Not always understood,

      Non-standard abbreviations and acronyms should be avoided, and the term should be written out in full.

    • The same applies when stating the pharmaceutical form in section 3 of the SmPC and section 4 of the labelling;
      i.e.
    • critical steps prior to administration of the product should also be included (section 5 of Annex IIIA).
    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 2/23

      Issues

      Connected problems

      QRD Suggestions

      emphasise in the labelling
      the special handling prior
      to administration of the
      product.

    • Consistency

      Inconsistencies in style are

      Once a particular style or house style has been selected, it must be used consistently throughout the text.

    • Tradename 150 mg solution for injection in pre-filled syringe
      Tradename 150 mg solution for injection in pre-filled pen

      information annexes?

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 3/23

      Issues
      Desiccant

      Connected problems

      QRD Suggestions

      For medicinal products

      The foil of blister packs containing a desiccant must be clearly labelled to show which blister pocket contains

      packaged with a desiccant

      the desiccant.

    • For bottles containing a desiccant, a similar statement should also be considered provided there

      mistake the desiccant for a

      is available space.

    • It can only be included in brackets in section 3 of the

      where can this be

      SmPC and section 4 of the labelling.

    • Direct speech should only
      be used in section 6 of the SmPC for instructions about shelf-life, storage, handling and disposal.
    • The term ?drug? though can be used in the product information annexes when it is part of a standard set of
      terms (e.g.
    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 5/23

      Issues
      Foreign terms

      Connected problems

      QRD Suggestions

      Foreign terms, particularly

      Foreign terms must be written in italics; e.g.

    • Patients can be referred to as ?he? or

      physician is often referred

      as ?she? when the medicinal product is exclusively for use by males or females.

    • if the product in question might be

      measurements are

      used by elderly patients), in brackets after the metric measures in the English text.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 6/23

      Issues

      Connected problems

      QRD Suggestions

      product name is composed
      of MAH+INN?

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 7/23

      Issues

      Connected problems

      QRD Suggestions
      MT: English
      BG: Bulgarian
      NL: Dutch
      CZ: Czech or English at applicant?s discretion.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 14/23

      Issues

      Connected problems

      QRD Suggestions
      considered, e.g.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 16/23

      Issues
      Symbols: Non-Unicode

      Connected problems

      QRD Suggestions

      The use of non-Unicode

      Only Unicode symbols must be used in submitted product information annexes.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 20/23

      Issues

      Connected problems

      Units: SI base units -

      International Standard

      litre

      base units have been
      introduced in the European
      Union with Council
      Directive 80/181/EEC of
      20.12.79 (O.J.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 23/23

Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration

Retrieved on: 
Monday, December 18, 2023

Charles River Laboratories International, Inc. (NYSE: CRL) today announced an important milestone in their strategic collaboration to manufacture CASGEVY™ (exagamglogene autotemcel [exa-cel]).

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced an important milestone in their strategic collaboration to manufacture CASGEVY™ (exagamglogene autotemcel [exa-cel]).
  • “We are pleased to reach this milestone working hand-in-hand with Vertex to manufacture the world’s first gene-edited therapy.
  • Charles River provides cell and gene-modified cell therapy developers with an efficient, robust, and scalable process to swiftly transition autologous and allogeneic programs to clinic and commercialization with one production partner.
  • Combined with the Company’s legacy testing capabilities, Charles River offers an industry-leading “concept-to-cure” advanced therapies solution.

WuXi Vaccines Wins Second Consecutive "Best Vaccine CMO Award" at AVEA 2023

Retrieved on: 
Wednesday, December 13, 2023

SINGAPORE, Dec. 12, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine Contract Development and Manufacturing Organization (CDMO), was named "Best Vaccine CMO of the Year" for the second consecutive year at the 2023 Asia-Pacific Vaccine Excellence Awards (AVEA) ceremony.

Key Points: 
  • SINGAPORE, Dec. 12, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine Contract Development and Manufacturing Organization (CDMO), was named "Best Vaccine CMO of the Year" for the second consecutive year at the 2023 Asia-Pacific Vaccine Excellence Awards (AVEA) ceremony.
  • WuXi Vaccines stood out among the nominees for its commitment to advancing global vaccine accessibility, especially in low and middle-income countries.
  • Mr. Jian Dong, CEO of WuXi Vaccines, commented, "We are deeply honored to receive the 'Best Vaccine CMO Award of the Year' for the second year.
  • Notably, WuXi Vaccines has played a crucial role in the fight against COVID-19 by manufacturing of hundreds of millions doses of COVID-19 vaccine, enabling our client to supply the vaccine to over 180 countries.

Yourway Receives Regulatory Approval and Commences Operations of New EU Flagship GMP Depot in Dublin

Retrieved on: 
Tuesday, October 24, 2023

Yourway, a global leader in integrated clinical supply solutions, today announced the opening of its latest flagship European GMP Depot strategically located in Dublin Airport Logistics Park.

Key Points: 
  • Yourway, a global leader in integrated clinical supply solutions, today announced the opening of its latest flagship European GMP Depot strategically located in Dublin Airport Logistics Park.
  • The GMP depot is located at:
    The Dublin GMP Depot spans 70,000 square feet (6,503 square meters) and was specifically designed to meet the diverse and specific needs of the EU.
  • "Our new GMP depot represents a milestone in our commitment to advancing clinical trials,” said Gulam Jaffer, Founder & President of Yourway.
  • This strategic location ensures swift and efficient distribution, linking EU trial sites and biopharma seamlessly with major transportation hubs worldwide.

WuXi Vaccines Launches Its First Vaccines CDMO Site in China

Retrieved on: 
Tuesday, September 26, 2023

SUZHOU, China, Sept. 26, 2023 /PRNewswire/ -- WuXi Vaccines, a leading contract development and manufacturing organization (CDMO) focused on vaccine discovery, development, and manufacturing, has launched its first standalone vaccines CDMO site in Suzhou, China.

Key Points: 
  • SUZHOU, China, Sept. 26, 2023 /PRNewswire/ -- WuXi Vaccines, a leading contract development and manufacturing organization (CDMO) focused on vaccine discovery, development, and manufacturing, has launched its first standalone vaccines CDMO site in Suzhou, China.
  • Mr. Jian Dong, CEO of WuXi Vaccines, commented, "We are very pleased with the opening at our first standalone vaccine CDMO site in China.
  • The WuXi Vaccines facility in Dundalk, Ireland, recently achieved its notable milestone and will initiate Tech Transfer (TT).
  • Currently, over 160 employees are working at the WuXi Vaccines Ireland site.

WuXi Vaccines Launches Its First Vaccines CDMO Site in China

Retrieved on: 
Tuesday, September 26, 2023

SUZHOU, China, Sept. 26, 2023 /PRNewswire/ -- WuXi Vaccines, a leading contract development and manufacturing organization (CDMO) focused on vaccine discovery, development, and manufacturing, has launched its first standalone vaccines CDMO site in Suzhou, China.

Key Points: 
  • SUZHOU, China, Sept. 26, 2023 /PRNewswire/ -- WuXi Vaccines, a leading contract development and manufacturing organization (CDMO) focused on vaccine discovery, development, and manufacturing, has launched its first standalone vaccines CDMO site in Suzhou, China.
  • Mr. Jian Dong, CEO of WuXi Vaccines, commented, "We are very pleased with the opening at our first standalone vaccine CDMO site in China.
  • The WuXi Vaccines facility in Dundalk, Ireland, recently achieved its notable milestone and will initiate Tech Transfer (TT).
  • Currently, over 160 employees are working at the WuXi Vaccines Ireland site.

MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing

Retrieved on: 
Wednesday, July 19, 2023

“Receiving our first commercial license for our state-of-the-art manufacturing facility in Shannon so rapidly is another testament to the quality of the MeiraGTx team and our industry leading end-to-end capabilities,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx.

Key Points: 
  • “Receiving our first commercial license for our state-of-the-art manufacturing facility in Shannon so rapidly is another testament to the quality of the MeiraGTx team and our industry leading end-to-end capabilities,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx.
  • The first facility was built to be a flexible and scalable center for viral vector production for clinical and commercial supply.
  • The second facility was built to manufacture plasmid DNA – the critical starting material for producing gene therapy products.
  • The third facility serves as a QC hub performing advanced biochemical quality control testing for release and stability testing for MeiraGTx and its partners' clinical and commercial programs.

WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations

Retrieved on: 
Monday, May 22, 2023

HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company a 2023 Facility of the Year Award (FOYA) in the Operations category.

Key Points: 
  • HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company a 2023 Facility of the Year Award (FOYA) in the Operations category.
  • WuXi Biologics was recognized for using innovative solutions while complying with regulatory requirements, overcoming unknown barriers, and upholding project success and product safety in its manufacturing facility in Dundalk, Ireland.
  • Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are very proud to be recognized by ISPE for the second time.
  • In 2014, WuXi Biologics was awarded the FOYA Honorable Mention for its manufacturing facility in Wuxi city, China.

WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations

Retrieved on: 
Monday, May 22, 2023

DUNDALK, Ireland, May 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.

Key Points: 
  • DUNDALK, Ireland, May 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.
  • WuXi Biologics was recognized for using innovative solutions while complying with regulatory requirements, overcoming unknown barriers, and upholding project success and product safety in its manufacturing facility in Dundalk, Ireland.
  • Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are very proud to be recognized by ISPE for the second time.
  • In 2014, WuXi Biologics was awarded the FOYA Honorable Mention for its manufacturing facility in Wuxi city, China.

Arriello appoints experienced Pharmacovigilance expert, Sam Tomlinson as VP of Global Drug Safety

Retrieved on: 
Wednesday, March 15, 2023

DUBLIN, March 15, 2023 /PRNewswire-PRWeb/ -- Arriello, a leading provider of integrated Regulatory Affairs, Pharmacovigilance (PV) and Auditing & QA solutions and services, has appointed distinguished Pharmacovigilance professional Sam Tomlinson to the position of VP of Drug Safety, where she will develop and direct clinical and non-clinical PV services and solutions, and lead the company's expanding multi-national PV team.

Key Points: 
  • Sam has over 20 years strategic and operational experience in global PV in both large pharma and small to medium-sized pharma organizations.
  • Commenting on her appointment, Sam said: "Arriello leads the field in providing innovative drug safety services to clients worldwide, so this is a great opportunity for me to contribute to the future of drug safety practices.
  • Arriello CEO and co-founder Alan White added, "Everyone at Arriello is delighted to welcome Sam on board as VP of Global Drug Safety.
  • Her extensive experience in PV will help us provide more comprehensive safety services across the entire product lifecycle.